6-deoxy-6-fluoronaltrexone and Alzheimer-Disease

6-deoxy-6-fluoronaltrexone has been researched along with Alzheimer-Disease* in 1 studies

Other Studies

1 other study(ies) available for 6-deoxy-6-fluoronaltrexone and Alzheimer-Disease

Article	Year
Opiate receptor avidity in the thalamus is sexually dimorphic in the elderly. Synapse (New York, N.Y.), 2000, Volume: 38, Issue:2 Opiate receptor avidity (B(')(max)/K(D)), was measured in the subcortex of nine females (five healthy subjects, four Alzheimer patients) and 15 males (seven healthy subjects, eight Alzheimer patients), 51-75 years of age, with the opiate receptor antagonist 6-deoxy-6-beta-[(18)F]fluoronaltrexone (cyclofoxy, CF) and a positron emission tomograph. CF avidity was 27.5% less in the thalamus of healthy women compared to healthy men and 48.5% less in Alzheimer disease female patients compared to male patients. Topics: Aged; Alzheimer Disease; Analysis of Variance; Female; Humans; Male; Middle Aged; Naltrexone; Receptors, Opioid; Regression Analysis; Sex Factors; Thalamus; Tomography, Emission-Computed	2000

Article

Year

Opiate receptor avidity in the thalamus is sexually dimorphic in the elderly.

Synapse (New York, N.Y.), 2000, Volume: 38, Issue:2

Opiate receptor avidity (B(')(max)/K(D)), was measured in the subcortex of nine females (five healthy subjects, four Alzheimer patients) and 15 males (seven healthy subjects, eight Alzheimer patients), 51-75 years of age, with the opiate receptor antagonist 6-deoxy-6-beta-[(18)F]fluoronaltrexone (cyclofoxy, CF) and a positron emission tomograph. CF avidity was 27.5% less in the thalamus of healthy women compared to healthy men and 48.5% less in Alzheimer disease female patients compared to male patients.

Topics: Aged; Alzheimer Disease; Analysis of Variance; Female; Humans; Male; Middle Aged; Naltrexone; Receptors, Opioid; Regression Analysis; Sex Factors; Thalamus; Tomography, Emission-Computed

2000